Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319309 | 0.93 | CES2 (0.61) | CRHBPCRHR2CES2CES1MAPT | |
| SCHEMBL29110778 | 0.87 | CRHBP (0.56) | CRHBPCRHR2CES2CES1MAPT | |
| SCHEMBL18304253 | 0.84 | CRHBP (0.52) | CRHBPCRHR2CES2CES1MAPT | |
| SCHEMBL668743 | 0.83 | NPC1 (0.63) | MAPTALDH1A1GSK3BL3MBTL1NPC1 | |
| SCHEMBL28872876 | 0.83 | PKM (0.62) | CES1MAPTALDH1A1GSK3BL3MBTL1 | |
| SCHEMBL8985359 | 0.83 | NPC1 (0.59) | CES1MAPTALDH1A1GSK3BL3MBTL1 | |
| SCHEMBL7129800 | 0.83 | MAPT (0.80) | CES2CES1MAPTL3MBTL1NPC1 | |
| SCHEMBL4477185 | 0.82 | CES1 (0.70) | CRHBPCRHR2CES2CES1MAPT | |
| SCHEMBL28532343 | 0.82 | ALDH1A1 (0.60) | CRHBPCRHR2CES2CES1MAPT | |
| SCHEMBL9207986 | 0.82 | CES1 (0.70) | CRHBPCRHR2CES2CES1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| CN-103547263-B | Cannabinoid receptor antagonists/inverse agonists useful for the treatment of metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY (US) | 2015-12-09 | — | — | CN | disclosed |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| CN-101842013-B | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY | 2015-04-15 | — | — | CN | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8648072-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2007131219-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | JENRIN DISCOVERY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007131219-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | JENRIN DISCOVERY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
| US-4037037-A | STABLE ENOLATE | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | CRHBP 4327/4885CRHR2 4827/4885CES2 3621/4885 |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CRHBP 601/4885CRHR2 107/4885CES2 864/4885 |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CRHBP 601/4885CRHR2 107/4885CES2 864/4885 |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | CRHBP 605/4885CRHR2 112/4885CES2 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.